Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Fence

Full company profile

uuid0023yc6

Namestring
Bio-Fence
Legal namestring
Bio-Fence Ltd.
Websiteurl
bio-fence.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 and headquartered in Jerusalem, focused on reducing morbidity and mortality from contaminated surfaces in healthcare and food-safety settings. The company has developed and commercialized a single product, OxiLast™ — a patented, water-based, film-forming antimicrobial coating formulation that is mixed with chlorine-based disinfectants and wipe-applied to non-porous, high-touch surfaces such as bed rails, bedside tables, mattresses, IV stands, light switches, door handles, and wheelchairs. The film preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, providing residual antimicrobial protection for up to 7 days and demonstrating ≥99.99% reduction of ESKAPE pathogens (MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) and Candida Auris within 5–15 minutes under challenging conditions including organic contamination and successive bacterial loadings.

The company has built scientific credibility through two core collaborations: in vitro efficacy studies at the Moran-Gilad Lab at Ben-Gurion University (resulting in a published Aric 2023 article) and a clinical effectiveness study at Hadassah Medical Center comparing OxiLast to the hospital's standard sanitation protocol against MRSA and Klebsiella pneumoniae on patient-room surfaces. Bio-Fence operates a B2B direct-sales motion initiated through structured website inquiry forms, with global country coverage and no publicly disclosed pricing. Revenue is generated via one-time product sales under a single-product line. The company has 1–10 employees, no disclosed external funding, no disclosed management team, and no disclosed commercial customers or revenue, indicating an early-stage, validation-phase commercial posture.

Short descriptiontext

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 that develops OxiLast™, a patented water-based antimicrobial coating extending chlorine's residual bactericidal activity for up to 7 days on high-touch surfaces in healthcare facilities and food-safety environments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial coatings, surface disinfection, infection prevention, healthcare hygiene, antimicrobial film technology
Industry2 codes
PRIMARYCRAJANAB
Concentrated Surface Disinfectants (Dilutable Liquids)
SECONDARYCRAJAMAB
Disinfecting All-Purpose Cleaners
SIC code1 code
  • Specialty Cleaning, Polishing And Sanitation Preparations2842
Product category
Antimicrobial Surface Coatings / Infection Prevention Products
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1OxiLast Antimicrobial Coating Product Sales
TypeOne Time License
Description

Bio-Fence generates revenue through the sale of their OxiLast patented antimicrobial coating product. The product is a film-forming formulation that is diluted with water and combined with chlorine tablets for application to surfaces in healthcare and food safety settings. The product is applied using a wipe-on method to inanimate non-porous surfaces.

bio-fence.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OxiLast
Description

Patented coating material that creates a long-lasting antimicrobial film, added to chlorine-based disinfecting solutions to preserve and extend bactericidal capacity for up to 7 days on surfaces.

bio-fence.com
Core offering1 text field

Bio-Fence develops and sells OxiLast, a patented water-based film-forming antimicrobial coating formulation designed to be added to chlorine-based disinfecting solutions. The product creates an invisible temporary film on surfaces that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual protection against healthcare-associated pathogens. The wipe-on product is intended for high-touch non-porous surfaces in healthcare facilities and food safety environments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >=99.99% reduction of ESKAPE pathogens (E. coli, MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) within 5-15 minutes, lasting up to 7 days
+2 more records
Product overview1 text field

Bio-Fence is a single-product company focused on healthcare infection prevention. Their flagship offering is OxiLast™, a patented antimicrobial coating technology that stabilizes chlorine-based disinfectants onto surfaces, creating a residual protective film that provides long-lasting antimicrobial activity for up to 7 days. The product is designed for healthcare settings to reduce healthcare-associated infections (HAIs) and combat antimicrobial resistance (AMR).

Product and service1 record
1OxiLast
CategoryAntimicrobial Surface Coating
Description

OxiLast is a patented water-based film-forming antimicrobial coating formulation designed to be diluted with water and combined with a chlorine tablet for wipe-on application to inanimate non-porous surfaces. It creates an invisible temporary film that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual antimicrobial activity against ESKAPE pathogens and Candida Auris. Intended for high-touch surfaces in healthcare facilities (patient rooms, bed rails, bedside tables, mattresses, IV stands, light switches, door handles, wheelchairs) and food safety environments.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Ben-Gurion University (Moran-Gilad Lab)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bio-Fence collaborated with the Moran-Gilad Lab at Ben-Gurion University to conduct comprehensive in vitro studies testing OxiLast's efficacy against ESKAPE pathogens. The studies demonstrated >=99.99% reduction of Gram positive and Gram negative ESKAPE organisms when applied to surfaces, with effectiveness lasting up to 7 days even under challenging conditions including simulated abrasion, organic contamination, and successive inoculations. Prof. Moran-Gilad (Prof. of Public Health and Clinical Microbiology) endorsed the technology as potentially being 'a game changer in the prevention of resistant infections.'

bio-fence.com
2Hadassah Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Hadassah Medical Center conducted a clinical effectiveness study of OxiLast in killing MRSA and Klebsiella pneumoniae on surfaces in actual patient rooms. Surfaces were treated once on day 0 (D0) and then contaminated with 106 CFU of resistant bacteria on consecutive days until day 7 (D7). The study compared OxiLast effectiveness against the hospital's current sanitation protocol, demonstrating significant reduction in live bacterial counts.

bio-fence.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Sciessent supplies antimicrobial and odor-control technologies (e.g., Agion) integrated into materials and surfaces. Adjacent emerging player offering an alternative additive-based antimicrobial mechanism relevant to Bio-Fence's high-touch-surface thesis.

TypeBroad incumbent
Description

PDI (Nice-Pak) is a leading manufacturer of disinfectant wipes (Sani-Cloth, Super Sani-Cloth) widely used in US hospitals. Comparable as an institutional disinfection incumbent with established hospital salesforce Bio-Fence must displace or partner with.

TypeDirect peer
Description

Halomine develops antimicrobial additive chemistries designed to be combined with common disinfectants to provide residual activity. Highly comparable mechanism and target use case (healthcare/food safety) to Bio-Fence's OxiLast.

TypeDirect peer
Description

HeiQ develops proprietary antimicrobial and hygiene technologies applied to surfaces and textiles (e.g., HeiQ Viroblock). Comparable as a residual-effect antimicrobial technology provider targeting infection prevention, with broader delivery formats than Bio-Fence.

TypeBroad incumbent
Description

Clorox Healthcare supplies disinfectants, sanitizers, and wipes used across US hospitals. A broad incumbent in healthcare surface disinfection that could leverage scale and distribution to launch a residual-efficacy competing product.

TypeBroad incumbent
Description

Ecolab is a global leader in infection prevention, healthcare hygiene, and surface disinfection. Comparable as a major, well-capitalized incumbent with the sales reach and R&D depth to either develop or acquire residual-coating capabilities competing with Bio-Fence.

TypeEmerging player
Description

Cupron embeds copper-based antimicrobial technology into textiles and surfaces for healthcare and consumer applications. Comparable as an emerging player using a different antimicrobial chemistry (copper) to address the same high-touch-surface infection-prevention pain point.

TypeDirect peer
Description

Allied BioScience develops long-lasting antimicrobial surface coatings (e.g., AEGIS Microbe Shield) for healthcare and high-touch environments. Directly comparable to Bio-Fence's OxiLast film-forming residual disinfection approach and target customers.

TypeDirect peer
Description

Kastus develops antimicrobial surface coatings that provide 24/7 protection against bacteria on glass, ceramics, and metals. Comparable technology approach (coatings delivering long-lasting antimicrobial activity) applied to shared infection-prevention pain points.

TypeDirect peer
Description

Israeli antimicrobial coating company commercializing surface-protective formulations used in medical and food settings. Directly comparable as a same-region, same-product-category peer focused on residual antimicrobial film technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Fence

Antimicrobial Surface Coatings / Infection Prevention Productsbio-fence.com

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 that develops OxiLast™, a patented water-based antimicrobial coating extending chlorine's residual bactericidal activity for up to 7 days on high-touch surfaces in healthcare facilities and food-safety environments.

What Bio-Fence does

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 and headquartered in Jerusalem, focused on reducing morbidity and mortality from contaminated surfaces in healthcare and food-safety settings. The company has developed and commercialized a single product, OxiLast™ — a patented, water-based, film-forming antimicrobial coating formulation that is mixed with chlorine-based disinfectants and wipe-applied to non-porous, high-touch surfaces such as bed rails, bedside tables, mattresses, IV stands, light switches, door handles, and wheelchairs. The film preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, providing residual antimicrobial protection for up to 7 days and demonstrating ≥99.99% reduction of ESKAPE pathogens (MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) and Candida Auris within 5–15 minutes under challenging conditions including organic contamination and successive bacterial loadings.

The company has built scientific credibility through two core collaborations: in vitro efficacy studies at the Moran-Gilad Lab at Ben-Gurion University (resulting in a published Aric 2023 article) and a clinical effectiveness study at Hadassah Medical Center comparing OxiLast to the hospital's standard sanitation protocol against MRSA and Klebsiella pneumoniae on patient-room surfaces. Bio-Fence operates a B2B direct-sales motion initiated through structured website inquiry forms, with global country coverage and no publicly disclosed pricing. Revenue is generated via one-time product sales under a single-product line. The company has 1–10 employees, no disclosed external funding, no disclosed management team, and no disclosed commercial customers or revenue, indicating an early-stage, validation-phase commercial posture.

Bio-Fence firmographics

Firmographics
Name
Bio-Fence
Legal name
Bio-Fence Ltd.
Website
https://bio-fence.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Bio-Fence Ltd. is a privately held Israeli company founded in 2017 that develops OxiLast™, a patented water-based antimicrobial coating extending chlorine's residual bactericidal activity for up to 7 days on high-touch surfaces in healthcare facilities and food-safety environments.
Ownership category
akta.pro rank

Bio-Fence industry classification

Industry
Product category
Antimicrobial Surface Coatings / Infection Prevention Products
SIC
Specialty Cleaning, Polishing And Sanitation Preparations (2842)
akta.pro industry
PRIMARYCRAJANAB
Concentrated Surface Disinfectants (Dilutable Liquids)
SECONDARYCRAJAMAB
Disinfecting All-Purpose Cleaners

Keywords

  • Antimicrobial coatings
  • Surface disinfection
  • Infection prevention
  • Healthcare hygiene
  • Antimicrobial film technology

Where Bio-Fence is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Bio-Fence business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

  1. OxiLast Antimicrobial Coating Product Sales: Bio-Fence generates revenue through the sale of their OxiLast patented antimicrobial coating product. The product is a film-forming formulation that is diluted with water and combined with chlorine tablets for application to surfaces in healthcare and food safety settings. The product is applied using a wipe-on method to inanimate non-porous surfaces.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Bio-Fence product offering

Product offering

Core offering

Bio-Fence develops and sells OxiLast, a patented water-based film-forming antimicrobial coating formulation designed to be added to chlorine-based disinfecting solutions. The product creates an invisible temporary film on surfaces that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual protection against healthcare-associated pathogens. The wipe-on product is intended for high-touch non-porous surfaces in healthcare facilities and food safety environments.

Product overview

Bio-Fence is a single-product company focused on healthcare infection prevention. Their flagship offering is OxiLast™, a patented antimicrobial coating technology that stabilizes chlorine-based disinfectants onto surfaces, creating a residual protective film that provides long-lasting antimicrobial activity for up to 7 days. The product is designed for healthcare settings to reduce healthcare-associated infections (HAIs) and combat antimicrobial resistance (AMR).

Differentiator

Problem solved

Functional benefit

Brands

  • OxiLast: Patented coating material that creates a long-lasting antimicrobial film, added to chlorine-based disinfecting solutions to preserve and extend bactericidal capacity for up to 7 days on surfaces.

Products and services

  • OxiLast OxiLast is a patented water-based film-forming antimicrobial coating formulation designed to be diluted with water and combined with a chlorine tablet for wipe-on application to inanimate non-porous surfaces. It creates an invisible temporary film that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual antimicrobial activity against ESKAPE pathogens and Candida Auris. Intended for high-touch surfaces in healthcare facilities (patient rooms, bed rails, bedside tables, mattresses, IV stands, light switches, door handles, wheelchairs) and food safety environments.

Quantifiable outcome

  • >=99.99% reduction of ESKAPE pathogens (E. coli, MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) within 5-15 minutes, lasting up to 7 days
  • +2 more outcomes

Companies that use Bio-Fence

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Bio-Fence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bio-Fence partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Ben-Gurion University (Moran-Gilad Lab)coreStrategic or Co-development PartnerBio-Fence collaborated with the Moran-Gilad Lab at Ben-Gurion University to conduct comprehensive in vitro studies testing OxiLast's efficacy against ESKAPE pathogens. The studies demonstrated >=99.99% reduction of Gram positive and Gram negative ESKAPE organisms when applied to surfaces, with effectiveness lasting up to 7 days even under challenging conditions including simulated abrasion, organic contamination, and successive inoculations. Prof. Moran-Gilad (Prof. of Public Health and Clinical Microbiology) endorsed the technology as potentially being 'a game changer in the prevention of resistant infections.'
  • Hadassah Medical CentercoreStrategic or Co-development PartnerThe Hadassah Medical Center conducted a clinical effectiveness study of OxiLast in killing MRSA and Klebsiella pneumoniae on surfaces in actual patient rooms. Surfaces were treated once on day 0 (D0) and then contaminated with 106 CFU of resistant bacteria on consecutive days until day 7 (D7). The study compared OxiLast effectiveness against the hospital's current sanitation protocol, demonstrating significant reduction in live bacterial counts.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Bio-Fence competitors and assessment

Company assessment

Emerging players

  • Sciessent: Sciessent supplies antimicrobial and odor-control technologies (e.g., Agion) integrated into materials and surfaces. Adjacent emerging player offering an alternative additive-based antimicrobial mechanism relevant to Bio-Fence's high-touch-surface thesis.
  • Cupron: Cupron embeds copper-based antimicrobial technology into textiles and surfaces for healthcare and consumer applications. Comparable as an emerging player using a different antimicrobial chemistry (copper) to address the same high-touch-surface infection-prevention pain point.

Broad incumbents

  • PDI Healthcare: PDI (Nice-Pak) is a leading manufacturer of disinfectant wipes (Sani-Cloth, Super Sani-Cloth) widely used in US hospitals. Comparable as an institutional disinfection incumbent with established hospital salesforce Bio-Fence must displace or partner with.
  • Clorox Healthcare: Clorox Healthcare supplies disinfectants, sanitizers, and wipes used across US hospitals. A broad incumbent in healthcare surface disinfection that could leverage scale and distribution to launch a residual-efficacy competing product.
  • Ecolab: Ecolab is a global leader in infection prevention, healthcare hygiene, and surface disinfection. Comparable as a major, well-capitalized incumbent with the sales reach and R&D depth to either develop or acquire residual-coating capabilities competing with Bio-Fence.

Direct peers

  • Halomine: Halomine develops antimicrobial additive chemistries designed to be combined with common disinfectants to provide residual activity. Highly comparable mechanism and target use case (healthcare/food safety) to Bio-Fence's OxiLast.
  • HeiQ Materials: HeiQ develops proprietary antimicrobial and hygiene technologies applied to surfaces and textiles (e.g., HeiQ Viroblock). Comparable as a residual-effect antimicrobial technology provider targeting infection prevention, with broader delivery formats than Bio-Fence.
  • Allied BioScience: Allied BioScience develops long-lasting antimicrobial surface coatings (e.g., AEGIS Microbe Shield) for healthcare and high-touch environments. Directly comparable to Bio-Fence's OxiLast film-forming residual disinfection approach and target customers.
  • Kastus: Kastus develops antimicrobial surface coatings that provide 24/7 protection against bacteria on glass, ceramics, and metals. Comparable technology approach (coatings delivering long-lasting antimicrobial activity) applied to shared infection-prevention pain points.
  • BioProtect: Israeli antimicrobial coating company commercializing surface-protective formulations used in medical and food settings. Directly comparable as a same-region, same-product-category peer focused on residual antimicrobial film technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Bio-Fence social profiles

Digital presence

Bio-Fence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Fence leadership team

Management profile

Number of profiles

Bio-Fence funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Fence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Fence

What does Bio-Fence do?

Bio-Fence develops and sells OxiLast, a patented water-based film-forming antimicrobial coating formulation designed to be added to chlorine-based disinfecting solutions. The product creates an invisible temporary film on surfaces that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual protection against healthcare-associated pathogens. The wipe-on product is intended for high-touch non-porous surfaces in healthcare facilities and food safety environments.

Is Bio-Fence a public or private company?

Bio-Fence is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bio-Fence founded?

Bio-Fence was founded in 2018. It employs 1 to 10 people.

Where is Bio-Fence based?

Bio-Fence is headquartered in Jerusalem, Israel, in the Middle East region.

How does Bio-Fence make money?

One revenue line is on record: oxiLast Antimicrobial Coating Product Sales.

Who are Bio-Fence's main competitors?

Emerging players on record are Sciessent and Cupron. Broad incumbents are PDI Healthcare, Clorox Healthcare and Ecolab. Direct peers are Halomine, HeiQ Materials, Allied BioScience, Kastus and BioProtect.

Does Bio-Fence have an API?

No public API is recorded for Bio-Fence.

What industry is Bio-Fence in?

Bio-Fence's product category is Antimicrobial Surface Coatings / Infection Prevention Products. Its primary akta.pro industry code is CRAJANAB, Concentrated Surface Disinfectants (Dilutable Liquids), with a secondary code of CRAJAMAB, Disinfecting All-Purpose Cleaners. Its SIC code is 2842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals